W K Hofmann, G Seipelt, S Langenhan, R Reutzel, D Schott, O Schoeffski, H J Illiger, F Hartmann, L Balleisen, A Franke, F Fiedler, C Huber, H Rasche, L Bergmann, A Ganser, C Pott, R Pasold, C Rudolph, O G Ottmann, N Gökbuget, D Hoelzer
In acute lymphoblastic leukemia (ALL), treatment with granulocyte colony stimulating factor (G-CSF) during remission induction shortens granulocytopenia and may decrease morbidity due to infections. However, the optimal timing of G-CSF administration after chemotherapy is not known. In a prospective randomized multi-center study, adult ALL patients were treated with high-dose ARA-C [HDAC, 3 g/m(2) bid (1 g/m(2) bid for T-ALL) days 1-4] and mitoxantrone (MI 10 mg/m(2) days 3-5). They were randomized to receive recombinant human G-CSF (Lenograstim) 263 micro g/day SC starting either from day 12 (Group 1) or day 17 (Group 2)...
October 2002: Annals of Hematology